Verastem ( ($VSTM) ) just unveiled an announcement. On August 13, 2025, Verastem announced updated safety and efficacy data from the VS-7375 Phase ...

The data, which will be presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, builds upon earlier results presented at ASCO. The study showed a disease control rate of 93.8% at the ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution ...

The mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key immune ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing ...

Research and development (R&D) expenses were $1.0 million for the quarter ended June 30, 2025 compared to $0.8 million for the quarter ended June 30, 2024. The $0.2 million increase was primarily due ...

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal ...